Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilertinib vs Gefitinib in First-Line EGFR-Mutated NSCLC
NCT04239833Phase 3Unknown
- Sponsor
- Nanjing Sanhome Pharmaceutical Co., Ltd.
- Start
- Jan 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of rilertinib in non-small cell lung cancer (NSCLC), sponsored by Nanjing Sanhome Pharmaceutical Co., Ltd.. Status: unknown.
02
Drugs
rilertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04239833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04239833.